Gilead Sciences, Merus collaborate to discover novel antibody-based trispecific T-cell engagers
Foster City: Gilead Sciences, Inc. and Merus N.V. have announced a research collaboration, option and license agreement to discover novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. Gilead and Merus agreed to collaborate on the use of Merus’ proprietary Triclonics platform along with Gilead’s oncology expertise to research and develop multiple, separate preclinical research programs. Merus […]